Cardiovascular Pulmonary PowerPoint Presentation Goal Develo

Cardiovascularpulmonary Powerpoint Presentationgoaldevelopa Powerpo

Develop a PowerPoint presentation on a cardiovascular/pulmonary disorder/disease discussed in the Dlugasch & Story textbook. The presentation must provide information about the incidence, prevalence, and pathophysiology of the disease/disorder at the cellular level. The presentation must educate advanced practice nurses on assessment and care/treatment, including genetics/genomics—specific to this disorder. Patient education for management, cultural, and spiritual considerations for care must also be addressed. The presentation must specifically address how the disease/disorder affects 1 of the following age groups: infant/child, adult, or elderly.

Paper For Above instruction

Introduction

Cardiovascular and pulmonary diseases represent a significant health burden globally, with particular implications across different age groups. Understanding the cellular mechanisms, epidemiology, and management strategies for these conditions is crucial for advanced practice nurses to provide comprehensive care. This paper focuses on pulmonary hypertension (PH), a complex cardiovascular disorder, emphasizing its impact on the elderly, and covers its incidence, prevalent statistics, cellular pathophysiology, assessment, treatment, genetics, and cultural considerations.

Incidence and Prevalence of Pulmonary Hypertension

Pulmonary hypertension is a progressive condition characterized by increased pressure in the pulmonary arteries, affecting approximately 15-50 cases per million population worldwide and about 25 cases per million in the United States (Simonneau et al., 2019). Its prevalence increases with age, and it is notably more common after age 60, predominantly impacting the elderly (Kwapisz & Farkas, 2020). The condition can be idiopathic or secondary to other diseases such as left heart failure, chronic lung diseases, or connective tissue disorders, which are more prevalent in older adults.

Pathophysiology at the Cellular Level

At the cellular level, pulmonary hypertension involves complex vasoconstrictive, proliferative, and remodeling processes within the pulmonary arteries. The abnormal proliferation of smooth muscle cells and endothelial dysfunction lead to thickening of the vessel wall, increased vascular resistance, and ultimately elevated pulmonary arterial pressures. Key molecular pathways involved include dysregulation of nitric oxide, prostacyclin, and endothelin-1, which influence vascular tone and cell proliferation (Zhao et al., 2021). In elderly patients, endothelial senescence and oxidative stress further exacerbate these processes, aggravating disease progression.

Assessment and Care/Treatment for Advanced Practice Nurses

Assessment involves detailed history-taking to identify symptoms such as dyspnea, fatigue, and syncope, along with diagnostic investigations like echocardiography, right heart catheterization, and biomarker analysis (Hoeper et al., 2019). Advanced practice nurses must be proficient in interpreting these findings and monitoring disease progression.

Therapeutic strategies aim to reduce pulmonary pressure and improve functional capacity. Pharmacological treatments include vasodilators such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. In elderly patients, careful consideration of pharmacodynamics, polypharmacy, and comorbidities is necessary to optimize therapy and minimize adverse effects (Galiè et al., 2022).

Genetics and Genomics

Genetic predisposition plays a role in some cases of pulmonary hypertension, especially heritable forms linked to mutations in the BMPR2 gene (Morse & Paul, 2020). Advances in genomics have identified other genetic variants influencing disease susceptibility and response to treatment. Incorporating genetic testing into clinical practice supports personalized management and helps identify at-risk populations among elderly patients with familial histories or predisposing conditions (Morse & Paul, 2020).

Patient Education and Cultural/Spiritual Considerations

Effective management includes educating patients about disease progression, medication adherence, lifestyle modifications, and recognizing symptoms indicating deterioration. For elderly patients, education must be tailored to cognitive status and health literacy levels, ensuring cultural sensitivity and respect for individual spiritual beliefs. Incorporating family and community support enhances adherence and coping strategies (Kozik et al., 2019). Awareness of cultural health practices may influence acceptance of certain therapies or dietary recommendations.

Conclusion

Understanding pulmonary hypertension from its cellular mechanisms to its clinical management is vital for advanced practice nurses, especially when caring for elderly patients. Tailored assessment, treatment, and patient education—considering genetic, cultural, and spiritual factors—are essential to improve outcomes and quality of life for this vulnerable population.

References

  • Galiè, N., Humbert, M., Vachiery, J.-L., et al. (2022). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 37(1), 67–119.
  • Hoeper, M. M., Bogaard, H. J., Condliffe, R., et al. (2019). Definitions and diagnosis of pulmonary hypertension. Journal of the American College of Cardiology, 71(1), 12–32.
  • Kozik, M., Siantz, E., & Williams, P. G. (2019). Culturally competent patient education for older adults. Journal of Nursing Practice, 15(2), 89–95.
  • Kwapisz, D., & Farkas, K. (2020). Pulmonary hypertension in older adults: Epidemiology and management considerations. Current Heart Failure Reports, 17(4), 131–138.
  • Morse, J. H., & Paul, K. (2020). Genetic insights into pulmonary arterial hypertension. Current Hypertension Reports, 22(5), 24.
  • Simonneau, G., et al. (2019). Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 73(17), 2389–2438.
  • Zhao, J., Li, S., & Gao, J. (2021). Molecular pathways in pulmonary hypertension: Role of nitric oxide, prostacyclin, and endothelin-1. Frontiers in Cardiovascular Medicine, 8, 624321.

Related Assignments